ATE306810T1 - Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse - Google Patents

Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse

Info

Publication number
ATE306810T1
ATE306810T1 AT03743372T AT03743372T ATE306810T1 AT E306810 T1 ATE306810 T1 AT E306810T1 AT 03743372 T AT03743372 T AT 03743372T AT 03743372 T AT03743372 T AT 03743372T AT E306810 T1 ATE306810 T1 AT E306810T1
Authority
AT
Austria
Prior art keywords
inbreeded
mice
stem cell
embryonal stem
derived mice
Prior art date
Application number
AT03743372T
Other languages
English (en)
Inventor
Ralf Kuehn
Anja Rode
Rudolph Jaenisch
Branco Zevnik
Original Assignee
Artemis Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artemis Pharmaceuticals Gmbh filed Critical Artemis Pharmaceuticals Gmbh
Application granted granted Critical
Publication of ATE306810T1 publication Critical patent/ATE306810T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00Cells related to new breeds of animals
    • C12N2517/02Cells from transgenic animals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/30Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03743372T 2002-03-05 2003-03-04 Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse ATE306810T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36216302P 2002-03-05 2002-03-05
PCT/EP2003/002180 WO2003073843A2 (en) 2002-03-05 2003-03-04 Inbred embryonic stem-cell derived mice

Publications (1)

Publication Number Publication Date
ATE306810T1 true ATE306810T1 (de) 2005-11-15

Family

ID=27789146

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03743372T ATE306810T1 (de) 2002-03-05 2003-03-04 Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse

Country Status (6)

Country Link
US (1) US20030204862A1 (de)
EP (1) EP1480515B1 (de)
AT (1) ATE306810T1 (de)
AU (1) AU2003210405A1 (de)
DE (1) DE60301953T2 (de)
WO (1) WO2003073843A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
GB2436737B (en) * 2006-03-30 2008-07-09 Univ Edinburgh Culture medium containing kinase inhibitors,and uses thereof
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
WO2007127254A2 (en) * 2006-04-25 2007-11-08 President And Fellows Of Harvard College Compositions and methods for generating transgenic animals
WO2009117439A2 (en) * 2008-03-17 2009-09-24 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
CA2800534C (en) 2010-06-11 2019-01-22 Regeneron Pharmaceuticals, Inc. Production of fertile xy female animals from xy es cells
KR102482184B1 (ko) 2010-12-22 2022-12-28 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
EP2471554A1 (de) 2010-12-28 2012-07-04 Hexal AG Pharmazeutische Formulierung mit biopharmazeutischem Arzneimittel
EP2511293A1 (de) 2011-04-13 2012-10-17 LEK Pharmaceuticals d.d. Verfahren zur Steuerung der Hauptkomplex-N-Glycan-Strukturen und der sauren Varianten und Variabilität in Bioprozessen, die rekombinante Proteine produzieren
SG11201600067YA (en) 2013-07-23 2016-02-26 Biocon Ltd Methods for controlling fucosylation levels in proteins
US11268069B2 (en) 2014-03-04 2022-03-08 Fate Therapeutics, Inc. Reprogramming methods and cell culture platforms
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
EP3161128B1 (de) 2014-06-26 2018-09-26 Regeneron Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur gezielten genetischen veränderung und verfahren zur verwendung
CN108697068B (zh) 2015-09-17 2022-02-11 瑞泽恩制药公司 对用于产生能生育的xy雌性小鼠的多能细胞的选择
CN108291237B (zh) 2015-10-16 2023-11-21 菲特治疗公司 用于诱导和维护基态多能性的平台
EP3403649A1 (de) 2017-05-16 2018-11-21 Bayer Pharma Aktiengesellschaft Inhibitoren und antagonisten von gpr84 zur behandlung von endometriose
EP3406253A1 (de) 2017-05-24 2018-11-28 Bayer Aktiengesellschaft Inhibitoren und antagonisten von humanem pycr1
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
WO2019233810A1 (en) 2018-06-04 2019-12-12 Bayer Aktiengesellschaft Inhibitors of shp2
CA3128793C (en) 2019-02-18 2023-02-28 Atb Therapeutics Method of producing a binder-toxin fusion protein in a plant cell or a whole plant
WO2020201195A2 (en) 2019-04-04 2020-10-08 Bayer Aktiengesellschaft Agonists of adiponectin
SG11202109901TA (en) 2019-04-09 2021-10-28 Hospital For Special Surgery Protein binders for irhom2
JP2022550390A (ja) 2019-09-30 2022-12-01 スキロム ゲゼルシャフト ミット ベシュレンクテル ハフツング iRhom2エピトープに結合するタンパク質バインダー
WO2021110796A1 (en) 2019-12-04 2021-06-10 Bayer Aktiengesellschaft Inhibitors of shp2
WO2022038152A1 (en) 2020-08-17 2022-02-24 Atb Therapeutics Recombinant immunotoxin comprising a ribotoxin or rnase
US20240317847A1 (en) 2021-02-26 2024-09-26 Bayer Aktiengesellschaft INHIBITORS OF IL-11 OR IL-11Ra FOR USE IN THE TREATMENT OF ABNORMAL UTERINE BLEEDING
KR20230150319A (ko) 2021-03-01 2023-10-30 사이롬 게임베하 iRhom2에 대한 인간화 항체
WO2022207652A1 (en) 2021-03-29 2022-10-06 Scirhom Gmbh Methods of treatment using protein binders to irhom2 epitopes
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
UY39967A (es) 2021-10-06 2023-05-15 Immatics Biotechnologies Gmbh Indicaciones para los aglutinantes anti-PRAME
US20230192886A1 (en) 2021-11-08 2023-06-22 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
KR20240150768A (ko) 2022-02-17 2024-10-16 에이티비 테라퓨틱스 리보솜 불활성화 단백질을 포함하는 재조합 면역독소
WO2024023246A1 (en) 2022-07-28 2024-02-01 Philogen S.P.A. Antibody binding to pd1
WO2024033362A1 (en) 2022-08-08 2024-02-15 Atb Therapeutics Humanized antibodies against cd79b
EP4659023A1 (de) 2023-02-03 2025-12-10 Immusmol SAS Verfahren zur vorhersage des erfolgs einer krebstherapie
AU2024283789A1 (en) 2023-06-05 2026-01-08 Pure Biologics Spólka Akcyjna Anti-garp antibodies and methods of use
KR20260020428A (ko) 2023-06-05 2026-02-11 퓨어 바이올로직스 스푸우카 아크치이나 항 ror1 항체 및 이의 사용 방법
WO2025040598A2 (en) 2023-08-18 2025-02-27 Immatics Biotechnologies Gmbh Peptides displayed by mhc for use in immunotherapy against different types of cancer
WO2025180665A1 (en) 2024-02-28 2025-09-04 Evotec International Gmbh Antibodies binding to cd2, and multifunctional molecules comprising such antibodies
WO2025242726A1 (en) 2024-05-21 2025-11-27 Onconick Ltd. Antibody binding to FGFR1 and conjugates comprising the same
CN119699269B (zh) * 2024-07-10 2025-10-17 太原市中心医院 基于sbsn 600位赖氨酸发生二羟基异丁酰化修饰的用于银屑病研究的小鼠模型构建方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9819912D0 (en) * 1998-09-11 1998-11-04 Univ Edinburgh Propagation and/or derivation of embryonic stem cells

Also Published As

Publication number Publication date
AU2003210405A1 (en) 2003-09-16
EP1480515B1 (de) 2005-10-19
DE60301953D1 (de) 2005-11-24
DE60301953T2 (de) 2006-07-27
WO2003073843A3 (en) 2004-01-22
US20030204862A1 (en) 2003-10-30
EP1480515A2 (de) 2004-12-01
WO2003073843A2 (en) 2003-09-12

Similar Documents

Publication Publication Date Title
ATE306810T1 (de) Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse
Zakka et al. A scientometric review of geopolymer concrete
CY1120316T1 (el) Εξανθρωπισμενοι ποντικοι fc γαμμα r
CY1113174T1 (el) Στελεχη ζυμων που παραγουν χοληστερολη και οι εφαρμογες τους
WO2011057163A3 (en) Intein-modified enzymes, their production and industrial applications
CY1116768T1 (el) Συνθεσεις οι οποιες περιεχουν βλαστοκυτταρα θηλυκης γαμετικης σειρας και μεθοδοι χρησης αυτων
ATE387724T1 (de) Solarzellenanordnung sowie verfahren zum verschalten eines solarzellenstrings
EA200401591A1 (ru) Керамические аноды и способ их изготовления
DK1576094T3 (da) Fremgangsmåder til at danne modificerede promotere resulterende i varierende genekspressionsniveauer
DK1948789T3 (da) Fremgangsmåde til fremstilling af permanente, humane cellelinjer
AR067114A1 (es) Metodos y composiciones para seleccionar loci en base al rendimiento y la exresion de caracteristicas
WO2006060126A3 (en) Heterologous alpha amylase expression in aspergillus
BRPI0520525A2 (pt) planta transgênica tendo toleráncia à seca intensificada
DK0972445T3 (da) Kimærisk mus som udtrykker et humant antistof
Estoque et al. The resilience–sustainability–quality of life nexus
EP1947180A4 (de) Transgene seidenraupe mit fähigkeit zur antikörperproduktion und verfahren zur herstellung davon
ATE408018T1 (de) Stress-resistenz als selektierbarer marker in transgenen pflanzen
DE60238766D1 (de) Veränderung des pflanzen genoms durch induzierbaren, ortspezifischen rekombination von transgenen
DE60134481D1 (de) MANIPULATION DES ALTERUNGSPROZESSES IN PFLANZEN MITTELS EINES i MYB / i GEN-PROMOTORS UND ZYTOKININ-BIOSYNTHESEGENEN
DE60335129D1 (de) VERFAHREN ZUR ERZEUGUNG VERBESSERTER ANTIKöRPER PRODUZIERENDER ZELLINIEN MIT VERBESSERTEN WACHSTUMSEIGENSCHAFTEN
NO20055210L (no) Inhibitorproteiner av en protease og anvendelse derav
WO2004007686A3 (en) Methods and transgenic mouse model for identifying and modulating factors involved in the production of reactive oxygen intermediates
DING et al. Factors influencing the population status of wild Chinese alligators (Alligator sinensis)
WO2006089152A3 (en) Use of methyltransferase inhibitors to enhance transgene expression
ATE446362T1 (de) Erzeugung von pflanzen mit verbesserter resistenz gegenüber krankheitserregern

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1480515

Country of ref document: EP

REN Ceased due to non-payment of the annual fee